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ABSTRACT:
DNA methylation of promoter sequences is a repressive epigenetic mark that 
down-regulates gene expression. However, DNA methylation is more prevalent 
within gene-bodies than seen for promoters, and gene-body methylation has been 
observed to be positively correlated with gene expression levels. This paradox 
remains unexplained, and accordingly the role of DNA methylation in gene-bodies 
is poorly understood. We addressed the presence and role of human gene-body 
DNA methylation using a meta-analysis of human genome-wide methylation, 
expression and chromatin data sets. Methylation is associated with transcribed 
regions as genic sequences have higher levels of methylation than intergenic or 
promoter sequences. We also find that the relationship between gene-body DNA 
methylation and expression levels is non-monotonic and bell-shaped. Mid-level 
expressed genes have the highest levels of gene-body methylation, whereas the 
most lowly and highly expressed sets of genes both have low levels of methylation. 
While gene-body methylation can be seen to efficiently repress the initiation of 
intragenic transcription, the vast majority of methylated sites within genes are not 
associated with intragenic promoters. In fact, highly expressed genes initiate the 
most intragenic transcription, which is inconsistent with the previously held notion 
that gene-body methylation serves to repress spurious intragenic transcription to 
allow for efficient transcriptional elongation. These observations lead us to propose 
a model to explain the presence of human gene-body methylation. This model holds 
that the repression of intragenic transcription by gene-body methylation is largely 
epiphenomenal, and suggests that gene-body methylation levels are predominantly 
shaped via the accessibility of the DNA to methylating enzyme complexes.
INTRODUCTION
DNA methylation is a crucial epigenetic mark 
with roles in embryogenesis and differentiation [1], 
X-inactivation [2], imprinting [3] and repression of viral 
and repeat sequences [4]. Changes in patterns of DNA 
methylation have been implicated in the pathogenesis of 
several human diseases [5, 6] including cancer [7]. One 
long established role of DNA methylation in promoter 
regions is the repression of transcription [1, 8, 9]. As a 
result, methylation is largely depleted from the promoter 
regions of genes. In contrast, DNA methylation in gene 
bodies is surprisingly abundant and has been reported to 
show a positive correlation with gene expression [10-15] 
even though it can interfere with transcription elongation 
[16]. The apparent contradiction between the activities 
of DNA methylation in promoters versus gene bodies 
has been referred to as the DNA methylation paradox 
[17]. Here, we address this paradox in an effort to better 
understand the presence and role of DNA methylation in 
human gene bodies. 
Repression of spurious transcription within genes is 
one possible explanation for the prevalence of gene-body 
methylation. Indeed, relatively low average levels of DNA Oncotarget 2012; 3:  462-474 463 www.impactjournals.com/oncotarget
methylation genome-wide have been taken to suggest 
that the primary role of methylation is the repression 
of spurious transcription rather than the regulation of 
promoters per se [18]. More recently, Cap Analysis of 
Gene  Expression  (CAGE)  data  have  confirmed  that 
transcription is very frequently initiated from within 
genes, albeit at lower levels than seen for canonical 5’ 
gene promoters [19, 20]. Thus, it is reasonable to assume 
that there may be some need to repress this intragenic 
transcription. Repression of intragenic promoters by DNA 
methylation could allow for more efficient transcriptional 
elongation, thus accounting for the reported positive 
correlations between gene expression and gene-body 
methylation levels. 
This model predicts a negative correlation between 
levels of gene-body methylation and the initiation of 
intragenic transcripts. Such a negative correlation was 
recently shown for the case of the human SHANK3 
locus where intragenic methylation regulates intragenic 
promoter activity [20]. This same study showed that within 
intragenic CpG islands genome-wide, there is an overall 
negative correlation between transcription initiation and 
methylation levels. Nevertheless, the extent to which this 
relationship holds across gene-bodies is unclear since 
there are numerous CpG sites and promoters outside of 
CpG islands [21]. 
The notion that gene-body methylation serves to 
repress intragenic transcription, thereby allowing for 
more  efficient  transcriptional  elongation  also  rests  on 
the reported clear and monotonic positive correlations 
observed between gene expression levels and gene-body 
methylation[11-15]. However, the relationship between 
Measurea Techniqueb Cell 
Typesc
GEO 
Accessionsd PMIDe
DNA methylation
Reduced representation bisulphite
sequencing
GM12878
K562
HepG2
HeLa-S3
H1hESC
GSE27584 18600261
Gene expression Exon microarray
GM12878
K562
HepG2
HeLa-S3
H1Hesc
HUVEC
GSE19090 19966280
Intragenic transcription 
initiation
Cap analysis of gene expression (CAGE)
GM12878
K562
HepG2
N/A
16489339
8938445
19074369
RNA Pol2 binding 
density
Chromatin immunoprecipitationfollowed 
by high-throughput sequencing (ChIP-
Seq)
GM12878
K562
HepG2
HeLa-S3
H1Hesc
HUVEC
GSE32465
17556576
17540862
19160518
18798982
DNaseI hypersensitive 
site density
DigitialDNaseI
GM12878
K562
HepG2
HeLa-S3
H1Hesc
HUVEC
GSE8962
GSE7411
15550541
16791208
aSpecificaspect of gene expression or chromatin being measured
bExperimentaltechnique or assay used
cENCODE cell types for which the data are available
dGene Expression Omnibus (GEO) accession numbers for the data
ePubMedIDs (PMID) for the references reporting the data
Table 1: Genome-wide expression and chromatin datasets analyzed in this studyOncotarget 2012; 3:  462-474 464 www.impactjournals.com/oncotarget
gene-body methylation and expression levels appears to 
be more complicated than previously imagined. In some 
plants and invertebrates, the relationship is not monotonic 
but rather bell shaped with genes expressed at the mid-
range levels having the highest methylation levels [22, 23]. 
More recently, when a variety human tissue types were 
analyzed, some showed a monotonic positive correlation 
between expression and gene-body methylation whereas 
others showed no apparent relationship [10]. Thus, 
it remains uncertain whether repression of spurious 
intragenic transcription best explains the high levels of 
observed gene-body DNA methylation. 
Here, we revisit this issue taking advantage of the 
recent accumulation of genome-scale datasets provided by 
the ENCODE [24, 25] and RIKEN groups. In particular, 
the availability of genome-wide human methylation [26], 
expression [19, 27-30] and chromatin datasets [31, 32] 
provide deep resolution for an interrogation of the DNA 
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Figure 1: DNA methylation levels around the TSS, gene-body and TTS across five gene expression level bins. (A) 
Average percentage methylation levels of 100bp windows spanning the TSS, gene-body and TTS, showing 3kb and 5kb upstream and 
downstream of TSS respectively and 5kb and 3kb upstream and downstream of TTS respectively. (B) Overall average (± standard error) 
percentage methylation levels for TTS, gene-body and TTS.Oncotarget 2012; 3:  462-474 465 www.impactjournals.com/oncotarget
methylation paradox. Meta-analysis of these genome-
scale data sets revealed that 1) the relationship between 
gene-body DNA methylation and gene expression is 
non-monotonic rather than linear, and 2) while gene-
body DNA methylation does serve to repress spurious 
transcription, that role does not explain the majority of 
methylation in gene-bodies. These results suggest a 
model whereby gene-body DNA methylation is chiefly 
determined by DNA accessibility to methylating enzymes 
during transcription, and the repression of intragenic 
transcription is simply an epiphenomenal byproduct of 
this process. The model accounts for the majority of gene-
body methylation, which cannot be explained by the need 
to repress spurious transcription alone. It also explains the 
observed non-monotonic relationship between gene-body 
DNA methylation and gene expression.
RESULTS
Meta-analysis of genome-wide methylation, 
expression and chromatin data sets
The ENCODE project has generated a rich collection 
of elements that associate with DNA sequences and have 
functional consequences for the way the genome is 
regulated. For this study, we made use of four datasets 
from the ENCODE project: 1) DNA methylation data 
generated by RRBS[26], 2) gene expression data 
generated from human exon microarrays[27, 28], 3) 
RNA polymerase II (Pol2) binding locations generated 
by ChIP-Seq [31, 33-36] and 4) the genomic locations 
of DNaseI hypersensitive sites (DHSS) generated by 
the digital DNaseI technique [32]. Additionally, we used 
a fifth dataset from the RIKEN Omics Science center 
made up of CAGE tags that characterize the 5’ ends of 
full-length  transcripts  [29]. All  five  of  these  datasets 
were available for three cell-lines (GM12878, K562 and 
HepG2), which together entail the primary focus of the 
study,  and  different  subsets  of  the  same  five  datasets 
were available in three additional cell-lines (HeLa-S3, 
H1hESC and HUVEC) (Table 1). These datasets were 
analyzed in various combinations across cell-lines in order 
to interrogate specific aspects of the relationship between 
DNA methylation, chromatin and gene expression.
A non-monotonic relationship between gene-body 
methylation and human gene expression
The DNA methylation paradox is borne of the fact 
that in human promoter regions CpG methylation is 
negatively correlated to gene expression levels, while in 
gene bodies CpG methylation is apparently positively 
correlated to gene expression [18]. Furthermore, recent 
genome-scale analyses of human methylation and gene 
expression suggest that this relationship is monotonic, 
i.e. gene-body methylation levels rise consistently across 
increasing intervals of gene expression [11, 13-15]. 
We further evaluated this paradoxical relationship 
using DNA methylation and gene expression data from 
ENCODE cell-lines (Table 1). To do this, percent DNA 
methylation values in-and-around gene-bodies were 
compared  across  five  gene  expression  level  quintiles. 
Consistent with previous reports in human cell-lines 
[11, 13], DNA methylation levels around transcription 
start sites (TSS) at the 5’ ends of genes show a clearly 
negative and monotonic correlation with gene expression 
levels (Figure 1 and Supplementary Material, Figure S1). 
The TSS regions of highly expressed genes are relatively 
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Figure 2: A non-monotonic relationship between gene-
body  DNA  methylation  and  gene  expression.  Overall 
percentage methylation of gene-bodies (regions starting at 1kb 
downstream of the TSS and ending at 1kb upstream of the TTS 
of genes) is regressed against gene expression for (A) GM12878 
(B) K562 and (C) HepG2. Genes are grouped into 100 gene 
expression bins.Oncotarget 2012; 3:  462-474 466 www.impactjournals.com/oncotarget
depleted for DNA methylation whereas genes expressed at 
lower levels are increasingly methylated. 
However, the relationship between gene-body 
methylation and expression levels is different from what 
has been described before; gene-body methylation levels 
show a bell-shaped, rather than monotonic, relationship 
with gene expression levels (Figure 1 and Supplementary 
Material, Figure S1). Generally, mid-level expressed 
genes in the 3rd and 4th quintiles have the highest DNA 
methylation percentages while those in the 2nd and 5th 
quintiles show medium DNA methylation percentages and 
those in the 1st quintile show the lowest DNA methylation 
percentages. A similar bell-shaped relationship between 
gene-body methylation and expression levels has been 
observed previously in plants (Arabidopsis thaliana and 
Oryza sativa) and invertebrates (Ciona intestinalis and 
Nematostella vectensis) [22, 23]. Human gene-body 
methylation levels measured here are about the same 
as those of the TTS regions but higher than those seen 
for both the regions surrounding TSS and the associated 
intergenic regions (Figure 1 and Supplementary Material, 
Figure S1). 
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Figure 3: Relationship between DNA methylation and promoter activity levels. Percent DNA methylation levels are regressed 
against CAGE expression levels (i.e. promoter activity) for (A) intronic and (B) canonical 5’ gene promoters. Genes are grouped into 100 
gene expression bins. Pearson correlation coefficient values (r) along with their significance values (P) are shown for each regression.Oncotarget 2012; 3:  462-474 467 www.impactjournals.com/oncotarget
In light of the unexpected but distinct non-monotonic 
relationship for human gene-body methylation and gene 
expression observed here, we sought to evaluate this 
pattern at a higher level of resolution. To do this, human 
genes were divided into 100 expression level bins, and then 
methylation and gene expression levels were regressed 
across these intervals. This analysis further revealed 
a clearly non-monotonic and bell-shaped relationship 
between gene-body methylation and gene expression in 
all five human cell lines for which methylation data was 
available (Figure 2 and Supplementary Material, Figure 
S2). The mid-level expressed genes showed the highest 
DNA methylation levels while both the lowest and highest 
expressed genes had markedly lower DNA methylation 
levels. 
DNA methylation levels have also been found to 
be related to gene length [37]. We thus sought to check 
if the bell-shaped relationship we found between gene-
body methylation and gene expression is not infact a 
reflection of the relationship between DNA methylation 
and gene length. To do this, we checked if the bell-shaped 
relationship would still be present for sets of genes 
with widely differing lengths. We found a similar bell-
shaped non-montonic relationship between gene-body 
methylation and gene expression for both the 20% shortest 
and 20% longest genes suggesting that the relationship 
is independent of gene length (Supplementary Material, 
Figure S3).
Gene-body methylation represses the initiation of 
intragenic transcription
DNA methylation was originally thought to serve 
primarily to repress spurious transcription [18], and gene-
body methylation has been shown to repress the activity 
of intragenic promoters [20]. Thus, it may be the case 
that gene-body methylation serves to repress spurious 
transcription from intragenic promoters, thereby allowing 
for more efficient transcriptional elongation. This kind 
of repressive role for DNA methylation could explain 
the relative abundance of DNA methylation within gene-
Fig 4 
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bodies and its reported positive correlation with gene 
expression.
To evaluate this possibility here, we used CAGE data 
to analyze the relationship between gene-body methylation 
and the repression of intragenic transcription. Intronic 
CAGE clusters mark intragenic promoters and the levels of 
transcriptional initiation from these intragenic promoters 
are characterized by the number of CAGE tags per intronic 
cluster [19, 20]. We mapped intragenic promoters across 
three ENCODE cell-lines using CAGE, and then DNA 
methylation levels at these intragenic promoters were 
regressed against the promoter activity levels measured 
by CAGE tag density. For all three cell-lines, this analysis 
revealed significantly negative correlations between the 
DNA methylation levels of intronic promoters and their 
corresponding transcriptional initiation levels (Figure 3A). 
These data are consistent with the repression of intragenic 
promoters by DNA methylation. Indeed, a similar analysis 
of canonical TSS from the 5’ ends of the genes, where the 
repressive role of DNA methylation is well known, yields 
qualitatively identical results (Figure 3B). 
Gene-body methylation, transcription and open 
chromatin 
Results from the previous section indicate that gene-
body methylation can repress intragenic transcription. 
Accordingly, if the primary role of gene-body methylation 
is to repress spurious intragenic transcription, then there 
should be more DNA methylation at intronic promoters 
than at intronic sites that do not initiate transcription. 
However, we find the vast majority of gene-body DNA 
methylation maps to sites that do not initiate transcription 
(Figure 4A). Presumably, this majority fraction of intronic 
DNA methylation does not serve to repress transcription. 
Furthermore, levels of gene-body methylation are highly 
positively correlated for these two classes of intronic 
sites: transcriptional initation sites and non-transcriptional 
initiation sites (Figure 4B-D). In other words, there 
is no particular enrichment of DNA methylation at 
intragenic promoters compared to their surrounding 
genic environment. Rather, DNA methylation levels are 
consistent across introns of individual gene-bodies and 
appear to be largely determined by something other than 
the need to repress intragenic transcription. 
These results instead suggest that gene-body DNA 
methylation is deposited onto introns by a mechanistically 
independent process, and that only a small fraction of 
the DNA methylated sites are involved in the silencing 
of spurious intragenic transcription. The relationship we 
observe between gene-body DNA methylation and gene 
expression (Figure 2) suggests that the transcriptional 
elongation process, together with its associated open 
chromatin, might account for much of gene-body 
methylation. If gene-body methylation is linked to 
transcriptional elongation, then transcribed regions 
would have higher levels of DNA methylation relative 
to un-transcribed regions. In fact, we observe that human 
genic regions do have substantially higher levels of DNA 
methylation than seen for intergenic regions (Figure 5 and 
Supplementary Material, Figure S4).  In addition, a similar 
elevation of DNA methylation levels for transcribed genic 
regions has been reported in a number of other species 
[22, 38]. 
DNA methylation is clearly associated with the 
presence of transcribed gene regions, and levels of 
transcription for these gene regions are expected to 
be associated with a distinct chromatin environment 
including high occupancy levels of Pol2 and the presence 
of demonstrably open chromatin. To test this, we regressed 
gene expression levels against Pol2 occupancy levels and 
the extent of open chromatin measured by the presence 
of DNaseI hypersensitive sites (DHSS). Both Pol2 
occupancy levels and the extent of open chromatin are 
in fact highly positively correlated with gene expression 
across all six ENCODE cell-lines evaluated here (Figure 
6 and Supplementary Material, Figure S5). 
When considered together with the data showing 
that gene-body methylation accumulates independent 
of the need to repress spurious intragenic transcription 
(Figure 4), these results suggest that the presence of 
open chromatin per se is an important prerequisite for 
the deposition of gene-body methylation. However, the 
relationship between gene-body methylation and open 
chromatin is non-monotonic, suggesting that the extent 
of open chromatin alone does not determine gene-body 
methylation levels. In the discussion section, we propose a 
specific model to explain the presence of gene-body DNA 
methylation that accounts for this complexity.
DISCUSSION 
DNA methylation is a well known repressive 
chromatin mark when associated with promoter regions. 
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Figure 5: Comparison between genic and intergenic 
average (± standard error) DNA methylation levels in 
GM12878, K562 and HepG2 cell-lines.Oncotarget 2012; 3:  462-474 469 www.impactjournals.com/oncotarget
However, DNA methylation is far more prevalent in 
gene-bodies than in promoters and the role of gene-body 
methylation is still not clearly understood. In this study, we 
performed a meta-analysis of genome-wide methylation, 
expression and chromatin data sets in an attempt to better 
understand the presence and role of gene-body DNA 
methylation.
We show that levels of DNA methylation are more 
clearly related to the presence of transcribed regions than 
to the impetus to repress spurious intragenic transcription. 
However, the quantitative relationship between gene-body 
methylation and expression levels in non-monotonic and 
bell-shaped. On the other hand, the relationships between 
gene expression levels and Pol2 occupancy along with 
open chromatin are positive and monotonic. Considered 
together, these results link gene-body methylation to 
transcription and open chromatin, albeit in a complex 
and non-linear way. Here, we propose a specific model to 
explain the presence of gene-body DNA methylation in 
light of these results.
Our model rests on the notion that the deposition 
of DNA methylation is mechanistically facilitated, to 
some extent, by open and actively transcribed chromatin. 
In support of this contention, a biochemical study 
demonstrated that DNA methyltransferase 1 (DNMT1) 
interacts with Pol2 by binding the C-terminal repeat 
domain of Pol2 [39]. It has also been shown that the 
catalytic domain of DNMT1 needs to directly bind to DNA 
and to transit along the DNA molecule in order to function 
[40, 41]. Nevertheless, the bell-shaped relationship 
between gene-body methylation and expression levels 
indicates that open and actively transcribed chromatin 
does not completely determine gene-body methylation. On 
the contrary, there appears to be some trade-off between 
the openness of the chromatin and the levels of DNA 
methylation, and we also try to account for this in our 
model. 
The model explaining levels of gene-body 
methylation is illustrated in Figure 7 and can be 
summarized as follows. The extent of nucleosome 
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packaging seen for unexpressed and compact chromatin 
would not allow for access to the DNA by DNMT1, 
effectively blocking DNA methylation. At low levels 
of transcription, transiting Pol2 complexes disrupt 
nucleosome packaging and open up the chromatin thereby 
exposing CpG sites for methylation. Therefore, levels of 
gene-body methylation will increase with increasing levels 
of expression at the low end of the expression spectrum. 
However, as genes become increasingly highly expressed, 
the density of transiting Pol2 becomes so high as to 
begin to interfere with the processivity of DNMT1 along 
DNA. This leads to a progressive reduction of gene-body 
methylation levels with increasing expression levels at the 
high end of the expression spectrum. Therefore, the most 
lowly and the most highly expressed genes will have the 
lowest levels of methylation, whereas genes expressed 
at intermediate levels will have the highest gene-body 
methylation, as seen here for humans and elsewhere for 
other species [22, 23].
While  we  find  this  model  to  be  mechanistically 
compelling for the reasons described above, it does not 
directly address the demonstrated role of gene-body DNA 
methylation in repressing spurious intragenic transcription. 
To investigate this further, we re-evaluated the intronic 
CAGE data in light of the non-monotonic relationship 
between gene expression and gene-body methylation 
levels. Regressing intronic CAGE levels against gene 
expression data and comparing this relationship to that 
seen for methylation and expression reveals a coincident 
inflection point between the two curves where methylation 
levels fall off to such an extent as to begin to allow for 
the initiation of transcription from intragenic promoters 
(Figure 8). This observation unites the DNA accessibility 
model for gene-body methylation that we propose with the 
role of methylation in repressing intragenic transcription. 
However, the juxtaposition of these two phenomena can 
also be taken to suggest the intriguing possibility that 
the observed repression of intragenic transcription by 
methylation is simply a by-product of relative accessibility 
levels to the DNA by methylating enzymes. 
The relationship between gene expression levels, 
Pol2 density and initiation of transcription from intragenic 
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Figure 7: Model showing how interactions between chromatin openness and Pol2 density specify gene-body DNA 
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promoters also serves to distinguish our observations 
and model from what has previously been proposed for 
A. thaliana [23]. The A. thaliana model also attempted 
to explain an observed bell-shaped distribution for gene-
body methylation with respect to expression, and the 
model held that gene-body methylation was facilitated by 
the transcription of siRNAs from intragenic promoters. 
Transcription of these intragenic siRNAs was thought to 
be facilitated by the progressive opening of the chromatin 
from low-to-mid levels of expression, and then these 
siRNAs would interact with their cognate DNA sequences 
to attract the methylation machinery in situ. However, 
at high levels of transcription, Pol2 density was thought 
to be too great to allow for the initiation of intragenic 
transcription thus accounting for the low levels of 
methylation for highly expressed genes. On the contrary, 
here we observe that the initiation of transcription from 
intragenic promoters increases steadily with increasing 
expression and Pol2 occupancy levels peaking among 
highly expressed genes that also show low levels of gene-
body methylation (Figure 8). 
It should also be noted that our observations on the 
relationship between expression level and gene-body 
methylation, at the high end of expression, are consistent 
with previous results showing that gene-body methylation 
interferes with transcriptional elongation [16]. Thus, the 
patterns observed here may also point to incompatibility 
and selection against high levels of gene-body methylation 
for highly expressed genes.
MATERIALS AND METHODS
Human gene loci
Gene annotations for the March 2006 build of the 
human genome reference sequence (NCBI build 36.1; 
UCSC hg18) were taken from the ‘RefSeq Genes’ track 
of the UCSC Genome Browser [42, 43]. Individual genes 
were defined as distinct genomic loci encompassing all 
overlapping RefSeq transcripts from the start of the 5’ 
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most exon to the end of the 3’ most exon. A total of 32,128 
RefSeq transcripts were merged into 19,539 genes that 
represent distinct gene loci.
DNA methylation
Genome-wide DNA methylation data for the 
GM12878, K562, HepG2, HeLa-S3 and H1Hesc cell-
lines were taken from the ‘ENCODE DNA methylation 
track’ of the UCSC Genome Browser (assembly hg19). 
Methylation data were generated using the Reduced 
Representation Bisulfite Sequencing (RRBS) technique 
[26] and cover approximately 1.26-1.47 million CpG sites 
in each of the five cell-lines. The RRBS methylation data 
are represented as percent methylation for each covered 
CpG site, and herein DNA methylation levels for any 
locus or genomic region were computed as the average 
percentage methylation of all cytosine residues covered 
therein. 
Gene expression
Exon microarray data for six ENCODE cell-lines 
(GM12878, K562, HepG2, HeLa-S3, H1Hesc and 
HUVEC) were taken from the ‘ENCODE Exon Array’ 
track of the UCSC Genome Browser (assembly hg19) 
[19, 27-30]. The data were generated using the Affymetrix 
Human Exon 1.0 ST GeneChip and analyzed using 
Affymetrix ExACT 1.2.1 software with samples quantile 
normalized using the PM-GCBG background correction 
and PLIER (probe logarithmic intensity error) summary. 
Here, the log2 normalized average signal intensity of all 
exons mapping to an individual gene locus was taken to 
represent the overall expression of the gene. This resulted 
into a final set of 18,632 genes for which expression data 
was available in all cell-lines. 
Cap Analysis of Gene Expression (CAGE) data 
[29, 30, 44] were taken from the ‘RIKEN CAGE Loci’ 
track of the UCSC Genome Browser (assembly hg18). 
Nucleus CAGE clusters for GM12878 (1.18 million), 
K562 (8.86 million) and HepG2 (5.89 million) cell-lines 
were analyzed here. Discretely located CAGE clusters 
were taken as individual proximal promoters (or TSS), and 
promoter expression levels were computed as the number 
of CAGE tags in a cluster divided by the length of the 
cluster. Intronic CAGE expression levels were calculated 
in the same way over entire gene loci. 
RNA Polymerase II (Pol2)
RNA Polymerase II (Pol2) binding site ChIP-seq 
data [31, 33-36] were taken from the ‘HAIB TFBS’ track 
of the UCSC Genome Browser (assembly hg18). The 
ChIP-seq reads were re-mapped to the human genome 
reference sequence (assembly hg18) in order to rescue 
individual tags that map to multiple genomic locations 
as previously described [45], resulting in approximately 
18.78, 6.78, 13.86, 6.78, 20.84, 22.61 and 12.34 million 
reads in the GM12878, K562, HepG2, HeLa-S3, H1Hesc 
and HUVEC cell-lines respectively. For each locus, Pol2 
binding density was computed as the number of tags 
mapping on the locus, divided by the length of the locus. 
DNaseI Hypersensitive Sites (DHSS)
DNaseI Hypersensitive Site (DHSS) data, generated 
using the digital analysis of chromatin structure (DACS) 
technique [32], were taken from the ‘UW DNaseI HS’ 
track of the UCSC Genome Browser (assembly hg18). 
The DACS sequence reads were re-mapped to the human 
genome reference sequence (assembly hg18) in order 
to rescue individual tags that map to multiple genomic 
locations as previously described [45], resulting in 
approximately 30.40, 35.15, 27.32, 44.10, 28.59 and 38.40 
million reads in the GM12878, K562, HepG2, HeLa-S3, 
H1Hesc and HUVEC cell-lines respectively. For each 
locus, DHSS density was computed as the number of tags 
mapping on the locus divided by the length of the locus.
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